Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 16,834 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia, Bacteremia
Interventions: UllCORE BSI Test; Diagnostic Test
Lead sponsor: Deepull Diagnostics S.L.; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Orange, California • Tampa, Florida • Baltimore, Maryland + 7 more

Conditions: Fanconi Anemia
Interventions: JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab; Drug · Device · Biological
Lead sponsor: Porteus, Matthew, MD; Other
Eligibility: 2 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
Interventions: Lacrifill, Saline; Drug
Lead sponsor: Eye Research Associates, LLC; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pittsburg, Kansas • Kansas City, Missouri

Conditions: HIV Infections, Acquired Immune Deficiency Syndrome, Sexually Transmitted Diseases, Viral
Interventions: CleverCap; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-Acute COVID-19 Syndrome
Interventions: HOPE-LC~Espanol; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Syndrome
Interventions: NAV5001, DaTscan; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Orlando, Florida

Conditions: Smith-Lemli-Opitz Syndrome, Pregnancy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Scarborough, Maine

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Myeloablative Conditioning, Pheresis, Recombinant Granulocyte Colony-Stimulating Factor; Procedure · Other · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts

Conditions: Lymphopenia
Interventions: nogapendekin-alfa inbakicept; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Metabolic Syndrome
Interventions: Blend 1, Blend 2, Placebo; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Cervical Disc Herniation, Cervical Disc Degeneration, Degenerative Disc Disease
Interventions: Tritanium C Anterior Cervical Cage; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions: Non-myeloablative Stem Cell Transplantation; Drug
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metabolic Syndrome
Interventions: MBSR; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stickler Syndrome Type 1, Stickler Syndrome Type 2
Interventions: Prophylactic (non-invasive) Laser Retinopexy; Procedure
Lead sponsor: Helen Keller Eye Research Foundation; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Royal Oak, Michigan + 3 more

Conditions: Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions: Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b; Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions: Not listed
Lead sponsor: AIDS Arms Inc.; Other
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obstructive Sleep Apnea
Interventions: This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1; Device
Lead sponsor: Nyxoah Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Miami, Florida • Summit, New Jersey

Conditions: Acute Coronary Syndrome, Thrombosis
Interventions: Aspirin 81 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome
Interventions: Ketone Ester Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Horsham, Pennsylvania

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Cemdisiran, Eculizumab, Pozelimab, Ravulizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whittier, California

Conditions: Diabetes Mellitus
Interventions: Alogliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 62
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 59 more

Search by objective public record fields.

Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Evaluation of Lacrifill

WiseApp for Spanish Speakers Living With HIV

Harnessing Optimism and Perseverance in the Face of Long COVID-Español

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Prenatal Screening For Smith-Lemli-Opitz Syndrome

Long-Term Survival With HIV: Psychological and Behavioral Factors Associated With the Transition From Adolescence to Young Adulthood

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome

Anterior Cervical Disectomy And Fusion Using The Tritanium® C Anterior Cervical Cage For One Or Two-Levels

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

Mindfulness Based Stress Reduction for Metabolic Syndrome

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation

Hormones Inflammation and Thrombosis

Ketone Esters for Appetite, Cognition, and Cardiovascular Function in Individuals With Obesity and Insulin Resistance

A Study of Patients Who Recently Have Been Infected With HIV

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus